Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07414784 · ClinicalTrials.gov registry record · Phase 1

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

A Phase 1 study of Healthy Volunteer, sponsored by AbbVie.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT07414784 is a Phase 1 study of Healthy Volunteer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 20 participants, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07414784, a Phase 1 study of Healthy Volunteer, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.

Conditions Studied

Interventions

  • DRUG ABBV-295
  • DRUG Levonorgestrel/Ethinyl Estradiol

Study Locations (1)

Illinois

  • ACPRU - Grayslake

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-02-11
Est. Completion 2026-07
Phase Phase 1

Sponsor

AbbVie

526 total trials

What the Registry Record Tells You About NCT07414784

The ClinicalTrials.gov registry entry for NCT07414784 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (90% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 2 interventions - of which ABBV-295 is the first listed.

NCT07414784 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT07414784 about?

NCT07414784 is a clinical study titled "A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives". This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.

What is the current status of trial NCT07414784?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-02-11. Estimated completion is 2026-07.

What conditions does trial NCT07414784 study?

This clinical trial studies the following conditions: Healthy Volunteer.

What interventions are being tested in trial NCT07414784?

The interventions under investigation include: ABBV-295 (DRUG), Levonorgestrel/Ethinyl Estradiol (DRUG).

Who is sponsoring clinical trial NCT07414784?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07414784 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.